Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marek Niedoszytko, Aleksandra Gorska, Knut Brockow, Patrizia Bonadonna, Magdalena Lange, Hanneke Kluin-Nelemans, Hanneke Oude-Elberink, Vito Sabato, Khalid Shoumariyeh, Dagmar von Bubnoff, Sabine Müller, Anja Illerhaus, Michael Doubek, Irena Angelova-Fischer, Olivier Hermine, Michel Arock, Chiara Elena, Luca Malcovati, Akif Selim Yavuz, Tanja Daniela Schug, Anna Belloni Fortina, Várkonyi Judit, Jason Gotlib, Jens Panse, Vladan Vucinic, Andreas Reiter, Juliana Schwaab, Massimo Triggiani, Mattias Mattsson, Christine Breynaert, Jan Romantowski, Roberta Zanotti, Elisa Olivieri, Alexander Zink, Annick van de Ven, Alex Stefan, Stephane Barete, Francesca Caroppo, Cecelia Perkins, Vanessa Kennedy, Deborah Christen, Mohamad Jawhar, Johannes Luebke, Roberta Parente, Kerstin Levedahl, Emir Hadzijusufovic, Karin Hartmann, Boguslaw Nedoszytko, Wolfgang R Sperr, Peter Valent
BACKGROUND: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry. METHODS: Data were collected in 27 ECNM centers. We analyzed potential triggers (Hymenoptera venoms, food, drug, inhalant and others) and risk factors at diagnosis and during follow-up...
April 23, 2024: Allergy
#2
JOURNAL ARTICLE
Mahanoor Baig, Nagesh C Nanjappa, Griffith B Perkins, Rachel Di Lernia, Venkatesan Thiruvenkatarajan, Pravin Hissaria
In Australia, neuromuscular blocking agents are the leading cause of perioperative anaphylaxis. Current investigation of suspected anaphylaxis includes tryptase levels, serum immunoglobulin E (IgE) levels, and skin testing, including intradermal testing and skin prick testing. The gold standard for the diagnosis of a hypersensitivity reaction is a challenge test, but this poses a risk to patient safety. An alternative test, known as the basophil activation test (BAT) is a form of cellular in vitro testing using flow cytometry to measure the degree of basophil degranulation within a sample of blood following exposure to an allergen...
April 22, 2024: Anaesthesia and Intensive Care
#3
JOURNAL ARTICLE
Morgan N Vincent, Jordon Jaggers, Christina Fiske, Elizabeth J Phillips, Joanna L Stollings
No abstract text is available yet for this article.
April 20, 2024: Annals of Allergy, Asthma & Immunology
#4
REVIEW
Simone Foti Randazzese, Ilenia Panasiti, Lucia Caminiti, Francesco Catamerò, Massimo Landi, Maria De Filippo, Martina Votto, Roberta Olcese, Filippo Favuzza, Mattia Giovannini, Salvatore Barberi
Peanut allergy affects about 1%-3% of the pediatric population in the world, with an important increase in the last decades. Nowadays, international guidelines recommend the early introduction of peanuts in the infant diet, with poor information about the quantity and the frequency of the intake. Allergen immunotherapy may represent the only therapeutic strategy able to modify the natural history of peanut allergy. In particular, oral immunotherapy showed the most promising results in terms of efficacy, but with significant rates of adverse reactions, mostly gastrointestinal...
April 2024: Pediatric Allergy and Immunology
#5
JOURNAL ARTICLE
Tsukasa Nozu, Hideyuki Arie, Saori Miyagishi, Masatomo Ishioh, Kaoru Takakusaki, Toshikatsu Okumura
Visceral hypersensitivity resulting from compromised gut barrier with activated immune system is a key feature of irritable bowel syndrome (IBS). Corticotropin-releasing factor (CRF) and Toll-like receptor 4 (TLR4) activate proinflammatory cytokine signaling to induce these changes, which is one of the mechanisms of IBS. As activation of the NLRP3 inflammasome by lipopolysaccharide (LPS) or TLR4 leads to release interleukin (IL)-1β, the NLRP3 inflammasome may be involved in the pathophysiology of IBS...
April 20, 2024: International Immunopharmacology
#6
REVIEW
Mariana Correia Marques, Michael J Ombrello, Grant S Schulert
INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory condition with onset in childhood. It is sporadic, but elements of its stereotypical innate immune responses are likely genetically encoded by both common variants with small effect sizes and rare variants with larger effects. AREAS COVERED: Genomic investigations have defined the unique genetic architecture of sJIA. Identification of the class II HLA locus as the strongest sJIA risk factor for the first time brought attention to T lymphocytes and adaptive immune mechanisms in sJIA...
April 20, 2024: Expert Review of Clinical Immunology
#7
REVIEW
Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith
PURPOSE OF REVIEW: Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid's content to better reflect patients' and caregivers' lived experience. RECENT FINDINGS: Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4-17 years old...
April 19, 2024: Current Allergy and Asthma Reports
#8
JOURNAL ARTICLE
Tomohiro Kagi, Aya Inoue, Takuya Noguchi, Wakana Suzuki, Saya Takano, Kohei Otani, Rio Naganuma, Yuto Sekiguchi, Yusuke Hirata, Sawako Shindo, Gi-Wook Hwang, Atsushi Matsuzawa
Drug-induced acute renal failure (ARF) is a public health concern that hinders optimal drug therapy. However, pathological mechanisms of drug-induced ARF remain to be elucidated. Here, we show that a pathological process of drug-induced ARF is mediated by proinflammatory cross-talk between kidney tubular cells and macrophages. Both polymyxin B and colistin, polypeptide antibiotics, frequently cause ARF, stimulated the ERK and NF-κB pathways in kidney tubular cells, and thereby upregulated M-CSF and MCP-1, leading to infiltration of macrophages into the kidneys...
April 19, 2024: Journal of Immunology
#9
JOURNAL ARTICLE
So-Young Park, So Young Park, Sujin Seo, Hyouk-Soo Kwon, Seung-Hyun Kim, Sae-Hoon Kim, Hye-Kyung Park, Yoon-Seok Chang, Cheol-Woo Kim, Byung Jae Lee, Hae-Sim Park, You Sook Cho, Heung-Bum Oh, David A Ostrov, Sungho Won, Tae Bum Kim
BACKGROUND: Drug-induced hypersensitivity such as anaphylaxis is an important cause of drug-related morbidity and mortality. Cefaclor is a leading cause of drug induced type I hypersensitivity in Korea, but little is yet known about genetic biomarkers to predict this hypersensitivity reaction. We aimed to evaluate the possible involvement of genes in cefaclor induced type I hypersensitivity. METHODS: Whole exome sequencing (WES) and HLA genotyping were performed in 43 patients with cefaclor induced type I hypersensitivity...
May 2024: World Allergy Organization Journal
#10
JOURNAL ARTICLE
Yongcai Gao, Lingli Zhou, Qiong Su, Qiang Li
INTRODUCTION: Major histocompatibility complex class II molecule (MHC-II) is pivotal in anti-tumor immunity, and targeting MHC-II in tumors may help improve patient survival. But function of MHC-II in the immunotherapy and prognosis of lung adenocarcinoma (LUAD) patients has not been thoroughly studied and reported. METHODS: We selected LUAD-related MHC-II genes from public databases based on previous literature reports. We identified different subtypes according to expression differences of these genes in different LUAD samples through cluster analysis...
April 18, 2024: International Archives of Allergy and Immunology
#11
REVIEW
Hyun J Yim, Tiffany Jean, Peck Y Ong
PURPOSE OF REVIEW: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD. RECENT FINDINGS: Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious...
April 18, 2024: Current Allergy and Asthma Reports
#12
JOURNAL ARTICLE
Jane Cy Wong, Andy Kc Kan, Thomas Sh Chik, M Y Chu, Timothy Cm Li, Hugo Wf Mak, Valerie Chiang, Philip H Li
BACKGROUND: Penicillin "allergy" labels are prevalent but frequently misdiagnosed. Mislabelled allergies are associated with adverse outcomes and increased antimicrobial resistance. With an urgent need to delabel the overwhelming number of mislabelled allergies, non-allergist evaluations have been advocated for low-risk individuals. Despite growing interest in non-allergist-led initiatives; evidence on their effectiveness, safety, and impact by direct comparisons are lacking. OBJECTIVE: We assessed the comparative outcomes of penicillin allergy evaluations conducted by allergists vs...
April 15, 2024: Journal of Allergy and Clinical Immunology in Practice
#13
JOURNAL ARTICLE
Zeynep Keskinkaya, Özge Kaya, Selda Işık Mermutlu, Zerrin Öğretmen
INTRODUCTION: Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of patients might complicate the prediction of the treatment outcomes. This study aimed to evaluate the effectiveness and safety of omalizumab in CSU patients, focusing on the factors predicting the response patterns. METHODS: This was a retrospective cross-sectional single-center study investigating CSU patients treated with omalizumab for at least 6 months between September 2015 and February 2023...
April 16, 2024: International Archives of Allergy and Immunology
#14
JOURNAL ARTICLE
Koya Fukunaga, Eri Tsukagoshi, Ryosuke Nakamura, Kayoko Matsunaga, Takeshi Ozeki, Hideaki Watanabe, Akito Hasegawa, Natsumi Hama, Maiko Kurata, Yoshiko Mizukawa, Yuko Watanabe, Yukie Yamaguchi, Hiroyuki Niihara, Eishin Morita, Hideo Asada, Riichiro Abe, Yoshiro Saito, Taisei Mushiroda
No abstract text is available yet for this article.
April 1, 2024: Journal of Allergy and Clinical Immunology in Practice
#15
JOURNAL ARTICLE
Carlos Fernández-Lozano, Claudia Geraldine Rita, Alicia Barra-Castro, Belén de la Hoz Caballer, Ernesto Roldán, Cristina Pueyo López, Javier Martinez-Botas, María Pilar Berges-Gimeno
Drug hypersensitivity reactions (DHRs) to platinum-based compounds (PCs) are on the rise, and their personalized and safe management is essential to enable first-line treatment for these cancer patients. This study aimed to evaluate the usefulness of the basophil activation test by flow cytometry (BAT-FC) and the newly developed sIgE-microarray and BAT-microarray in diagnosing IgE-mediated hypersensitivity reactions to PCs. A total of 24 patients with DHRs to PCs (20 oxaliplatin and four carboplatin) were evaluated: thirteen patients were diagnosed as allergic with positive skin tests (STs) or drug provocation tests (DPTs), six patients were diagnosed as non-allergic with negative STs and DPTs, and five patients were classified as suspected allergic because DPTs could not be performed...
March 31, 2024: International Journal of Molecular Sciences
#16
JOURNAL ARTICLE
Remy S Petersen, Lauré M Fijen, Christian Apfelbacher, Markus Magerl, Karsten Weller, Werner Aberer, Adil Adatia, Paul Audhya, Noémi-Anna Bara, Stephen Betschel, Isabelle Boccon-Gibod, Laurence Bouillet, Nicholas Brodszki, Paula J Busse, Thomas Buttgereit, Anette Bygum, Mauro Cancian, Timothy Craig, Dorottya Csuka, Henriette Farkas, Daria Fomina, Johana Gil-Serrano, Mark Gompels, Guillermo Guidos Fogelbach, Mar Guilarte, Michihiro Hide, Sorena Kiani-Alikhan, Tamar Kinaciyan, Annet Lenten, Ramon Lleonart, Hilary Longhurst, William R Lumry, Alejandro Malbran, Laura Malinauskiene, Juan J Matta Campos, Joan Mendivil, Sandra A Nieto-Martinez, Jonathan G Peter, Grzegorz Porebski, Avner Reshef, Marc Riedl, Anna Valerieva, Susan Waserman, Marcus Maurer, Danny M Cohn
BACKGROUND: Clinical trials investigating drugs for acute treatment of hereditary angioedema attacks have assessed many different outcomes. This heterogeneity limits comparability of trial results and may lead to selective outcome reporting bias and a high burden on trial participants. OBJECTIVE: To achieve consensus on a Core Outcome Set comprising key outcomes that should ideally be utilized in all clinical efficacy trials involving acute treatment of hereditary angioedema attacks...
April 10, 2024: Journal of Allergy and Clinical Immunology in Practice
#17
JOURNAL ARTICLE
Şule Büyük Yaytokgil, Ahmet Selmanoglu, Ilknur Kulhas Celik, Zeynep Şengül Emeksiz, Tayfur Ginis, Betül Karaatmaca, Muge Toyran, Ersoy Civelek, Emine Dibek Misirlioğlu
INTRODUCTION: There are limited data regarding the characteristics and management of drug hypersensitivity reactions (DHR) in hospitalized children. This study aims to determine the prevalence, clinical features, and management of DHRs in pediatric inpatients. METHODS: Children who had pediatric allergy consultation for suspected DHR during hospitalization in Ankara Bilkent City Hospital between August 1, 2020, and July 30, 2021, were included. Patient and reaction characteristics, culprit drugs, and management strategies were recorded...
April 2024: World Allergy Organization Journal
#18
REVIEW
Thomas B Casale, Alessandro Fiocchi, Matthew Greenhawt
The recent approval of omalizumab for the treatment of IgE-mediated food allergy is an important step forward for the millions of food allergy patients in the US. Through the depletion of circulating IgE and the subsequent reduction of FCεR1 on key effector cells, patients increase their tolerance to food allergens. However, omalizumab does not permit patients to eat foods that they are allergic to with impunity. Rather, it protects them from most accidental exposures. In addition, omalizumab does not cure food allergy and has not demonstrated true immunomodulation...
April 8, 2024: Journal of Allergy and Clinical Immunology
#19
Naharuthai Bumrungratanayos, Songphol Tungjitviboonkun
A 56-year-old Thai male, known for allergies to penicillin, sulfa, and lincosamide, presented with hyperferritinemia. Upon initiating deferiprone therapy, the patient experienced recurrent episodes of dyspnea, culminating in anaphylactic shock. Treatment included subcutaneous epinephrine, intravenous chlorpheniramine, and hydrocortisone, which led to symptom resolution. This case constitutes the first case report of deferiprone-associated anaphylactic reactions.
April 2024: Curēus
#20
JOURNAL ARTICLE
Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, Chuang-Wei Wang
BACKGROUND: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock. There is no method to predict or prevent ADRs caused by oxaliplatin. Therefore, we aimed to investigate the genetic HLA predisposition and immune mechanism of oxaliplatin-induced ADRs. METHODS: A retrospective review was performed for 154 patients with ADRs induced by oxaliplatin during 2016-2021 recorded in our ADR notification system...
April 8, 2024: Allergology International: Official Journal of the Japanese Society of Allergology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
